BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ · Healthcare
BridgeBio Oncology Therapeutics, Inc. Operating Income 2023–2025
BridgeBio Oncology Therapeutics, Inc. annual/quarterly operating income history and growth rate from 2023 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- BridgeBio Oncology Therapeutics, Inc. operating income for the quarter ending March 31, 2026 was -46.2 M, a 99.59% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. operating income for the twelve months ending March 31, 2026 was -168.9 M.
- BridgeBio Oncology Therapeutics, Inc. annual operating income for 2025 was -145.8 M, a 80.33% increase from 2024.
- BridgeBio Oncology Therapeutics, Inc. annual operating income for 2024 was -80.9 M, a 24.84% increase from 2023.
- BridgeBio Oncology Therapeutics, Inc. annual operating income for 2023 was -64.8 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
BridgeBio Oncology Therapeutics, Inc. Operating Income — FAQ
BridgeBio Oncology Therapeutics, Inc. (BBOT) operating income over the last 3 years — annual and quarterly figures with year-over-year growth and charts.
What is BridgeBio Oncology Therapeutics, Inc.'s operating income?
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported operating income of -$146M for fiscal 2025.
Where can I see BBOT's operating income history?
The chart and table above show BridgeBio Oncology Therapeutics, Inc.'s operating income by year and by quarter, including the growth rate.